Introduction
Dravet syndrome (severe myoclonic epilepsy in infancy) is characterized by febrile and afebrile, generalised and partial seizures that start in the first year of life. Later, myoclonic seizures, atypical absences and developmental delay occur. Seizures are often therapy-resistant to antiepileptic drugs. Antiepileptic treatment with valproic acid (VPA), clobazam and stiripentol or the combination of VPA and topiramate (TPM) is often advised. Acute hepatic injury is a possible complication of many drugs. Acute VPA-induced liver toxicity is fatal in the majority of patients. 1 Especially in very young children the risk is high; the risk of fatal liver failure in children under 2 years of age receiving VPA as polytherapy is 1:600. In children between 3 and 10 years using VPA polytherapy the risk is 1:8.300. 2 The relation between TPM and hepatotoxicity has been Seizure (2008) Summary We describe four children with Dravet syndrome treated with the combination of valproic acid (VPA) and topiramate (TPM) who developed transient liver toxicity. The time-interval between fever, administration of acetaminophen, epileptic status and liver enzyme disturbances in our four cases suggests that accumulation of toxic acetaminophen-metabolites is possibly responsible for liver toxicity. If acetaminophen and its metabolites cause those liver problems in children treated with the combination of VPA and TPM, the advice to use acetaminophen for treating fever in children using this combination, should be changed. suggested before in two case-reports. 3, 4 However, in both publications the adult patients used multiple antiepileptic drugs including TPM. No reports on hepatotoxicity in children or adults receiving TPM monotherapy have been published till now. There is evidence that ingestion of acetaminophen in therapeutic dosages can cause an evident rise in alanine aminotransferase (ALAT) in 31-44% of healthy, adult volunteers. 5 We describe four children with Dravet syndrome who developed a serious rise of liver enzymes. All were treated with the combination of VPA, TPM and acetaminophen.
Case report
Case No. 1, a 5-month-old boy from non-related parents visited our outpatient clinic because of generalised tonic-clonic seizures and partial seizures with rhythmic twitches of the tongue and facial musculature. EEG registration showed multifocal spikes and for this reason carbamazepine (CBZ) was started. Metabolic screening revealed no aminoaciduria, no organic aciduria and normal serum total, free, and acyl-carnitine concentrations. Cerebrospinal fluid analysis and MRI scan showed no abnormalities. Because of the fact that his seizure frequency worsened and myoclonic seizures were noted, CBZ was withdrawn and VPA was initiated at the age of 8 months. Several episodes of epileptic status occurred, triggered by febrile episodes.
He was admitted to Kempenhaeghe epilepsy centre for further analysis and treatment. At the age of 12 months, TPM was added to his medication and gradually increased, because of ongoing seizures. The diagnosis of Dravet syndrome was confirmed when a c.2684T > G (p.Leu895Arg) mutation was found in exon 15 of the SCN1A gene.
At the age of 15-month, he suffered from an epileptic status triggered by influenza B infection. The day before, he was given acetaminophen 240 mg q.i.d. (73 mg/kg/day) by his parents in order to suppress his fever. A rise in liver enzymes was noted, and L-carnitine 100 mg/kg/day was started on the day of admission. His antiepileptic medication was continued in dosages equal to those before admission and acetaminophen was stopped. ASAT (2229 U/l) and ALAT (2022 U/l) levels peaked at day 1. Coagulation times were increased (APTT 20.9 s; INR 2.1). Screening for Hepatitis virus A, B and C, Epstein-Barr virus and Cytomegalovirus was negative. A spontaneous decrease of transaminases and coagulation parameters to almost normal values was noticed in the week after admission. On discharge, L-carnitine was added to his regular medication.
Three months later, he was admitted again to the paediatric intensive care unit because of an epileptic status triggered by fever (39.5 8C) of unknown origin. Also this time, his parents had given him acetaminophen. The rise of liver enzymes and coagulation disturbance was even more severe now (ASAT 7326 U/l; ALAT 5203 U/l; APTT 24.4 s; PT 32 s; INR 2.6). VPA concentration was 45 mg/L (normal range 40-100 mg/L). Transaminases gradually normalised despite the continuation of VPA, TPM, and L-carnitine. Also this time, screening for viral hepatitis was negative.
The medical histories of Case No. 1 and the other three children are summarised in Table 1 . Antiepileptic drug concentrations were only measured in case 1 (second episode), 3 and 4. All parents used acetaminophen according to the manufacturers instructions. The dose used at home was not documented at admission in the other children. It is important to note that case Nos. 1 and 3 developed a rise in liver enzymes while receiving adequate Lcarnitine prophylaxis (advised dose: 100 mg/kg/ day 6,7 ). In case No. 2, carnitine concentration was measured on the day of admission. At that moment she showed a serious rise in transaminases. Total, free, and acyl-carnitine concentrations in plasma were normal. In case Nos. 3 and 4 the rise of transaminases was less impressive, however a significant elevation of ammonia was noted. Because of the serious rise in ammonia, a partial ornithine transcarbamylase deficiency was ruled out in both children.
Discussion
In Dravet syndrome (severe myoclonic epilepsy in infancy), seizures are often therapy-resistant. In a randomized add-on study, the addition of stiripentol to VPA and clobazam has been shown effective in Dravet syndrome. 8 The efficacy of TPM in Dravet syndrome has been proven in an open label study 9 and in a retrospective analysis, adding TPM to the combination of VPA, clobazam, and stiripentol seemed helpful. 10 In recent literature discussing the treatment of Dravet syndrome, the combination of VPA and TPM is advised, together with strict acute seizure treatment and prevention of hyperthermia.
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The molecular basis of Dravet syndrome is a mutation of the SCN1A gene expressing a sodium channel alpha subunit. This sodium channel is only expressed in neuronal tissue, so a relation between liver failure and the SCN1A gene mutation does not seem obvious.
VPA-induced hepatic failure has been related to carnitine deficiency. Chronic use of VPA leads to a VPA-induced liver toxicity in caused by several co-occurring mechanisms. L-carnitine supplementation is often recommended in young children who are receiving VPA, especially those younger than 2 years with a complex neurological disorder who are receiving multiple antiepileptic drugs. 6, 13 The efficacy of L-carnitine supplementation has never been determined, but only one child developing VPAinduced liver failure while receiving adequate Lcarnitine supplementation has been reported. 14 In a retrospective analysis, it has been shown that the survival in patients with severe VPA-induced hepatotoxicity is significantly higher after treatment with L-carnitine (48% versus 10% without L-carnitine suppletion).
1 IV treatment is associated with significant better survival than enteral treatment. 1 TPM is frequently used in children. In a recent large open-label study, no rise in liver enzymes was observed in any of the 277 children (age: 12 months and 16 years) treated with add-on TPM. 15 No reports on hepatotoxicity after the introduction of TPM monotherapy have been published till now.
A causal relation between TPM and hepatotoxicity has been mentioned in two case-reports. 3, 4 However, both adults used polypharmacy (Table 2) . Longin et al. 16 reported a child and Bumb et al. 17 reported an adult, both treated with VPA/TPM polytherapy who developed an elevation of liver enzymes ( Table 2 ). Both patients were on stable VPA dosage while TPM was gradually increased. Those reports provide anecdotal evidence that TPM increases the risk of liver toxicity when added to VPA.
Liver enzymes normalised in case No. 1 in both episodes although both VPA and TPM were continued. In case Nos. 3 and 4 TPM was continued and VPA initially stopped but reintroduced in an equal dose without problems. This probably implicates that there have to be other mechanisms beside the exposure to VPA and TPM. A potential mechanism for liver damage especially in this group is the rigorous treatment of fever with acetaminophen. Searching Medline and PUBMED, we have not been able to find any interaction between VPA and acetaminophen or TPM and acetaminophen. However, the time-interval between fever, ingestion of acetaminophen, seizures and discovery of liver enzyme disturbances in our four cases and normal carnitine concentrations at admission in case No. 3, suggest that accumulation of metabolites of acetaminophen, due to inhibition of cytochrome P450 enzymes by VPA and TPM, is possibly responsible for hepatotoxicity. Another mechanism could be reduced glururonide conjugation of acetaminophen due to the fact that this pathway is already used in VPA elimination. A very interesting study found that stiripentol is able to prevent hepatic necrosis after acetaminophen overdose in rats. 18 Stiripentol inhibits the synthesis of N-acetyl-p-benzoquinoneimine, a highly reactive metabolite. 18 In clinical practice, the combination of stiripentol, VPA, and TPM seems safe; in a retrospective series of 24 children no liver problems were reported. 10 Case No 1. received 73 mg/kg/day acetaminophen. It is advised that the daily dose should not exceed 75 mg/kg. 19 However, also the use of acetaminophen in normal dose can lead to an elevation of transaminases. In a recent paper, 145 healthy volunteers were treated in a placebo-controlled study with 4 g of acetaminophen for 14 days. 31-44% of acetaminophen-treated adults showed a maximum ALAT concentration of more than 3 times the upper limit of normal. 5 This result implicates that doctors need to be aware that ingestion of acetaminophen in doses that are thought to be safe, might lead to raised transaminases. 20 If acetaminophen and its metabolites cause those liver problems in children treated with the combination of VPA and TPM, the advice to use acetaminophen for treating fever in children using this combination, should be changed. Only future observations or research can solve this dilemma.
An important interaction between VPA and TPM in the clinical presentation of hyperammonic encephalopathy has been reported in several case reports. The combination of VPA and TPM can give rise to a deterioration of encephalopathy by two different mechanisms. I; TPM inhibits the carbonic anhydrase enzyme and this has been shown to increase ammonia levels. 21 In this situation, cessation of TPM results in a decrease of ammonia and subsequent improvement of symptoms despite continuation of VPA. 21 II; The other mechanism results in deterioration of symptoms of encephalopathy without a rise of venous ammonia concentrations. This is a result of inhibition of the glutamine synthetase enzyme by TPM. Glutamine synthetase is essential in the breakdown of ammonia and glutamate inside neurons, so inhibition leads to an increase of intracellular ammonia concentrations. In several patients reported, consciousness improved significantly after withdrawal of TPM, although venous ammonia levels did not change.
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Conclusion
We report four young children diagnosed with Dravet syndrome that developed a rise in liver enzymes (and a rise of ammonia in two children) after admission because of an epileptic status. All were treated with VPA and TPM and with acetaminophen because of fever the days before admission. It is important to note that liver toxicity occurred in two children while they had adequate L-carnitine supplementation. The clinical course of those four children supposes that there may be other mechanisms beside the exposure to TPM and VPA.
The time-interval between fever, acetaminophen, epileptic status and liver enzyme disturbances in our four cases suggests that accumulation of toxic acetaminophen-metabolites is possibly responsible for the liver toxicity. Only future research and clinical observations can solve this clinical problem.
